Latest Insider Transactions at First Wave Bio Pharma, Inc. (FWBI)
This section provides a real-time view of insider transactions for First Wave Bio Pharma, Inc. (FWBI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of First Wave BioPharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of First Wave BioPharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 09
2024
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
476
-2.57%
|
$0
$0.45 P/Share
|
|
Jul 02
2024
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
621
-3.25%
|
$621
$1.07 P/Share
|
|
Jul 02
2024
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
1,289
-3.47%
|
$1,289
$1.07 P/Share
|
|
Jun 11
2024
|
Chaitan Phd Khosla Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,889
+50.0%
|
-
|
|
Apr 01
2024
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
75
-0.39%
|
$300
$4.23 P/Share
|
|
Apr 01
2024
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
174
-0.47%
|
$696
$4.23 P/Share
|
|
Mar 15
2024
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,120
-5.52%
|
$4,480
$4.96 P/Share
|
|
Mar 15
2024
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
1,887
-4.82%
|
$7,548
$4.96 P/Share
|
|
Mar 13
2024
|
Chaitan Phd Khosla Director |
BUY
Grant, award, or other acquisition
|
Indirect |
440
+50.0%
|
-
|
|
Mar 13
2024
|
Jack Syage President & COO |
BUY
Grant, award, or other acquisition
|
Indirect |
15,400
+50.0%
|
-
|
|
Jan 12
2024
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
166
-0.42%
|
$664
$4.2 P/Share
|
|
Jan 12
2024
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
98
-0.48%
|
$392
$4.2 P/Share
|
|
Jan 02
2024
|
Edward Borkowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,633
+49.23%
|
-
|
|
Jan 02
2024
|
Mary Theresa Coelho Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,633
+49.24%
|
-
|
|
Jan 02
2024
|
Alastair Riddell Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,633
+49.24%
|
-
|
|
Jan 02
2024
|
Charles J Casamento Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,633
+49.62%
|
-
|
|
Jan 02
2024
|
James Sapirstein Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.71%
|
-
|
|
Jan 02
2024
|
Sarah Romano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+25.54%
|
-
|
|
Dec 29
2023
|
James Sapirstein Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,660
+47.74%
|
-
|
|
Dec 29
2023
|
Sarah Romano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,614
+48.48%
|
-
|
|
Oct 04
2023
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
2,764
-7.64%
|
$0
$0.29 P/Share
|
|
Oct 04
2023
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,676
-9.59%
|
$0
$0.29 P/Share
|
|
Sep 15
2023
|
Charles J Casamento Director |
SELL
Open market or private sale
|
Direct |
10
-0.16%
|
$0
$0.43 P/Share
|
|
Aug 31
2023
|
Charles J Casamento Director |
SELL
Open market or private sale
|
Direct |
6,053
-49.77%
|
$0
$0.3 P/Share
|
|
Jul 03
2023
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
3,349
-8.48%
|
$3,349
$1.54 P/Share
|
|
Jul 03
2023
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,977
-10.16%
|
$1,977
$1.54 P/Share
|
|
Apr 03
2023
|
Sarah Romano Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,975
-9.22%
|
$3,950
$2.5 P/Share
|
|
Apr 03
2023
|
James Sapirstein Chairman and CEO |
SELL
Open market or private sale
|
Direct |
3,347
-7.81%
|
$6,694
$2.5 P/Share
|
|
Jan 03
2023
|
James Sapirstein Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
Jan 03
2023
|
Sarah Romano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Jan 03
2023
|
Mary Theresa Coelho Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,745
+50.0%
|
-
|
|
Jan 03
2023
|
Alastair Riddell Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,745
+49.87%
|
-
|
|
Jan 03
2023
|
Charles J Casamento Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,745
+49.89%
|
-
|
|
Jan 03
2023
|
David Andrew Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,745
+48.28%
|
-
|
|
Jan 03
2023
|
Edward Borkowski Director |
BUY
Grant, award, or other acquisition
|
Direct |
84,745
+49.59%
|
-
|